Search results
25 sty 2023 · Immunoglobulin treatment for Kawasaki disease. Key message. In children with Kawasaki disease, high‐dose intravenous immunoglobulin (IVIG) regimens: • probably reduce the risk of coronary artery abnormalities formation compared to aspirin or medium‐ or low‐dose IVIG regimens; • show no clear safety concerns;
- 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease
The Kawasaki Disease Comparative Effectiveness Trial...
- Kawasaki disease: a comprehensive review - PMC - National Center for ...
Kawasaki disease is treated with intravenous immunoglobulin...
- 2021 Update on the Clinical Management and Diagnosis of Kawasaki Disease
6 lut 2021 · The Kawasaki Disease Comparative Effectiveness Trial (KIDCARE) is a phase III, 2-arm, randomized, multicenter, superiority treatment study to compare infliximab to the 2nd-dose IVIG for treatment of children with IVIG resistance that was recently completed with results to be published.
25 sty 2023 · The primary treatment is intravenous immunoglobulin (IVIG) and acetylsalicylic acid (ASA/aspirin), with doses and regimens differing between institutions. It is important to know which regimens are the safest and most effective in preventing complications.
10 lut 2023 · The frequency of CA aneurysm development and associated morbidity and mortality have dramatically decreased as a result of treatment with intravenous immune globulin (IVIG). This therapy is effective for preventing CA abnormalities, but the benefits in children who have already developed CA aneurysms are more equivocal.
26 paź 2021 · Infliximab is a safe, well tolerated, and effective treatment for patients with IVIG resistant Kawasaki disease, and results in shorter duration of fever, reduced need for additional therapy, less severe anaemia, and shorter hospitalisation compared with second IVIG infusion.
Immunoglobulin treatment for Kawasaki disease. Key message. In children with Kawasaki disease, high-dose intravenous immunoglobulin (IVIG) regimens: • probably reduce the risk of coronary artery abnormalities formation compared to aspirin or medium- or low-dose IVIG regimens; • show no clear safety concerns;
21 mar 2018 · Kawasaki disease is treated with intravenous immunoglobulin (IVIG) and high dose aspirin, although the use of aspirin in the management has been controversial in some studies [22–24]. A meta-analysis showed that the use of corticosteroids with IVIG as initial treatment has a better effect on reducing the risk of coronary artery abnormalities ...
